UNSPSC 51162628: Fedrilate maleate

This classification denotes an antitussive agent C20H29NO4.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7UF5M66EUR, chemically known as 2h-pyran-4-carboxylic acid, tetrahydro-4-phenyl-, 1-methyl-3-(4-morpholinyl)propyl ester, (2z)-2-butenedioate (1:1), but more generally known as fedrilate maleate, which bears US NIH Compound Identifier 71587508. European Medicines Agency schedules Fedrilate maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02105MIG.

Most nations, for tariff and trade purposes, schedule fedrilate maleate under HS 29349990 and SITC 51579. As of Q4 2014, FEDRILATE MALEATE remains US FDA's Preferred Term for this commodity. SMILES: CC(CCN1CCOCC1)OC(=O)C2(CCOCC2)C3CCCCC3.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51162628 Fedrilate maleate is a Commodity code that nominally covers a specific pharmaceutical compound, but recent state and local procurement activity tagged to this code shows minimal alignment with the code's narrow scope. The two most recent opportunities present a significant mismatch: Seminole County, Florida's IFB for naloxone and drug deactivation systems, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. Neither solicitation references fedrilate maleate specifically, suggesting either a tagging error in the source data or that this code is being used as a catch-all classification for pharmaceutical procurement that does not fit more granular commodity codes. State and local issuing bodies using this code appear limited to county health departments and multi-state cooperative purchasing alliances focused on community health and pharmacy support.

The geographic spread based on recent activity is concentrated in Florida and the upper Midwest (Minnesota and Oregon), with no other states represented in the available opportunities. Seminole County's IFB, posted June 30, 2026 with a response deadline of July 26, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida. MMCAP's RFP, posted January 20, 2026 with a response deadline of March 26, 2026, establishes multi-vendor contracts for generic pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) across member facilities, with awarded vendors' products to become available July 1, 2026. Neither opportunity discloses explicit set-aside designations. The code shows sparse recent activity with weak relevance to its stated commodity name.